학술논문

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Document Type
article
Source
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2051-1426